Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Science 37 Holdings stock price, quote, forecast and news

SNCE
US8086441081

Price

5.75
Today +/-
+0
Today %
+0 %
P

Science 37 Holdings stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Science 37 Holdings stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Science 37 Holdings stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Science 37 Holdings stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Science 37 Holdings's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Science 37 Holdings Stock Price History

DateScience 37 Holdings Price
3/22/20245.75 undefined
3/21/20245.75 undefined

Science 37 Holdings Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Science 37 Holdings, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Science 37 Holdings from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Science 37 Holdings’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Science 37 Holdings. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Science 37 Holdings’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Science 37 Holdings’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Science 37 Holdings’s growth potential.

Science 37 Holdings Revenue, EBIT and net profit per share

DateScience 37 Holdings RevenueScience 37 Holdings EBITScience 37 Holdings Net Income
2027e138.71 M undefined14.28 M undefined0 undefined
2026e107.52 M undefined2.43 M undefined0 undefined
2025e76.68 M undefined-21.33 M undefined-398.25 M undefined
2024e64.07 M undefined-21.16 M undefined-411.64 M undefined
2023e59.53 M undefined-33.77 M undefined-684.45 M undefined
202270.15 M undefined-105.32 M undefined-50.99 M undefined
202159.6 M undefined-63.72 M undefined-94.33 M undefined
202023.7 M undefined-31.69 M undefined-31.67 M undefined
201923.7 M undefined-31.69 M undefined-31.67 M undefined

Science 37 Holdings Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20192020202120222023e2024e2025e2026e2027e
23235970596476107138
--156.5218.64-15.718.4718.7540.7928.97
4.354.3528.8121.43-----
11171500000
-31-31-63-105-33-21-21214
-134.78-134.78-106.78-150.00-55.93-32.81-27.631.8710.14
-31-31-94-50-684-411-39800
--203.23-46.811,268.00-39.91-3.16--
115.49115.49115.49115.8800000
---------
Details

Keystats

ⓘ

Revenue and Growth

The Science 37 Holdings Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Science 37 Holdings is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (k)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
201920202020202120212022
           
32.50.4232.50.42214.6108.1
11.2011.2010.711
000000
000000
2.40.122.40.127.47.1
46.10.5446.10.54232.7126.2
2.702.703.50
080.12080.1200
000000
8.108.1024.30
000000
20002000300200
1180.121180.1228.10.2
57.180.6657.180.66260.8126.4
           
143.175.53143.175.5300
1.65.561.65.56323.7350.2
-107.7-0.56-107.7-0.56-202.1-253.1
00000200
000000
3780.533780.53121.697.3
4.40.134.40.1312.87.2
8.808.8017.111.4
5.105.105.14.6
000000
000000
18.30.1318.30.133523.2
000000
000000
1.801.80104.25.9
1.801.80104.25.9
20.10.1320.10.13139.229.1
57.180.6657.180.66260.8126.4
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Science 37 Holdings provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Science 37 Holdings's financial health and stability.

Assets

Science 37 Holdings's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Science 37 Holdings must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Science 37 Holdings after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Science 37 Holdings's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
201920202020202120212022
-310-310-94-50
4040717
000000
00008-13
202041-28
000000
000000
-250-250-36-75
-60-60-20-31
-6-80-6-80-20-31
0-800-8000
000000
000000
-32-322380
368136812380
3978397800
000000
4040181-106
-31.65-0.58-31.65-0.58-57.06-107.31
000000

Science 37 Holdings stock margins

The Science 37 Holdings margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Science 37 Holdings. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Science 37 Holdings.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Science 37 Holdings's sales revenue. A higher gross margin percentage indicates that the Science 37 Holdings retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Science 37 Holdings's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Science 37 Holdings's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Science 37 Holdings's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Science 37 Holdings. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Science 37 Holdings's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Science 37 Holdings Margin History

Science 37 Holdings Gross marginScience 37 Holdings Profit marginScience 37 Holdings EBIT marginScience 37 Holdings Profit margin
2027e22.62 %10.29 %0 %
2026e22.62 %2.26 %0 %
2025e22.62 %-27.82 %-519.38 %
2024e22.62 %-33.02 %-642.52 %
2023e22.62 %-56.72 %-1,149.7 %
202222.62 %-150.14 %-72.69 %
202128.86 %-106.91 %-158.27 %
20204.68 %-133.71 %-133.63 %
20194.68 %-133.71 %-133.63 %

Science 37 Holdings Stock Sales Revenue, EBIT, Earnings per Share

The Science 37 Holdings earnings per share therefore indicates how much revenue Science 37 Holdings has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Science 37 Holdings earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Science 37 Holdings's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Science 37 Holdings’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Science 37 Holdings's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Science 37 Holdings Revenue, EBIT and net profit per share

DateScience 37 Holdings Sales per ShareScience 37 Holdings EBIT per shareScience 37 Holdings Earnings per Share
2027e1.16 undefined0 undefined0 undefined
2026e0.9 undefined0 undefined0 undefined
2025e0.64 undefined0 undefined-3.34 undefined
2024e0.54 undefined0 undefined-3.45 undefined
2023e0.5 undefined0 undefined-5.73 undefined
20220.61 undefined-0.91 undefined-0.44 undefined
20210.52 undefined-0.55 undefined-0.82 undefined
20200.21 undefined-0.27 undefined-0.27 undefined
20190.21 undefined-0.27 undefined-0.27 undefined

Science 37 Holdings business model

Science 37 Holdings Inc. is a company specializing in clinical trials supported by technology and digital methods. It was founded in 2014 by a team of experienced medical and technological experts. The company is headquartered in Los Angeles, California, USA. Science 37's business model focuses on accelerating clinical trials and reducing costs by facilitating access to patients and data through a digital, telemedicine-based infrastructure. This is changing the way clinical trials are conducted by addressing one of the biggest obstacles to industrial development: the lengthy recruitment of patients. The various divisions of Science 37 include a platform for telemedicine studies, which allows virtual researchers to assess and connect with patients remotely, an in-house platform for clinical data management and analysis, and an extensive network of physicians and patients who offer and participate in clinical studies. Science 37's partners include pharmaceutical companies, biotech companies, academic institutions, and government agencies. Science 37 offers a wide range of products tailored to the specific needs of its customers. These products include: 1. NORA - A telemedicine platform for near-site recruitment, which allows patients to conveniently participate in a clinical trial through their own device. The platform provides a seamless and integrated experience for the patient and facilitates collaboration between study centers and virtual researchers. 2. NEST - A platform for clinical studies designed for the management of large data-driven studies. NEST provides a central database that simplifies the collection and management of study data and complies with compliance requirements. 3. SIV - A cloud-based platform for site initiation visits, which allows sponsors to accelerate study initiation with a wealth of site information without the need for an on-site visit. 4. Decentralized Clinical Trials - A fully digital platform that supports a clinical study from recruitment to data analysis and uses the "bring your own device" paradigm (BYOD). Decentralized Clinical Trials allow access from anywhere, whenever the patient desires. The company has an impressive track record, having worked on more than 27 clinical trials and being awarded numerous accolades, including "Most Innovative Clinical Trial Solution Provider" at the Global Health & Pharma (GHP) Awards 2019. Overall, Science 37 is an innovative company that has revolutionized the way clinical trials are conducted. Technology has the potential to radically transform medical research and accelerate drug development. Science 37 is pushing the boundaries of what is possible in large-scale patient recruitment and is a key player in the digital transformation of clinical research. Science 37 Holdings is one of the most popular companies on Eulerpool.com.

Science 37 Holdings SWOT Analysis

Strengths

Science 37 Holdings Inc has several strengths that contribute to its success in the market:

  • Innovative Technological Platform: Science 37 utilizes a cutting-edge technological platform to conduct decentralized clinical trials, offering a unique and efficient approach in the industry.
  • Agile and Adaptive Processes: The company's ability to adapt quickly to changes and optimize its processes allows for streamlined operations and faster trials, giving Science 37 a competitive edge.
  • Strong Industry Partnerships: Science 37 has established strategic partnerships with leading pharmaceutical companies, enhancing its reputation and facilitating access to a wider range of potential clients and trials.

Weaknesses

Despite its strengths, there are some weaknesses that Science 37 Holdings Inc should address:

  • Limited Market Penetration: While Science 37 has made significant progress, it still faces challenges in gaining widespread adoption of its decentralized clinical trial model, as traditional methods and approaches remain deeply ingrained in the industry.
  • Dependence on Technological Infrastructure: Being heavily reliant on technology exposes Science 37 to potential glitches or technical disruptions, which could impact the smooth execution of trials and overall client satisfaction.
  • Sustainability Concerns: The long-term sustainability of decentralized clinical trials is still uncertain, as market acceptance and regulatory changes remain key factors that may impact Science 37's growth and profitability.

Opportunities

Science 37 Holdings Inc can leverage the following opportunities to further expand its market presence:

  • Rise in Remote Healthcare: The growing trend of telehealth and remote healthcare presents a significant opportunity for Science 37 to offer its decentralized clinical trial services to a wider audience, as remote patient participation becomes increasingly accepted.
  • Increasing Need for Efficiency: As the healthcare industry seeks more cost-effective and time-efficient approaches, Science 37's streamlined processes and ability to conduct trials without geographical constraints positions the company well to cater to these needs.
  • Emerging Markets: Expanding into emerging markets that have a more receptive regulatory environment for decentralized clinical trials can open up new avenues for growth and diversification for Science 37.

Threats

Science 37 Holdings Inc should be aware of the following threats that could impact its operations:

  • Regulatory Challenges: Evolving regulations and varying degrees of acceptance for decentralized clinical trial models across different regions can pose challenges for Science 37's expansion efforts.
  • Competition: The field of decentralized clinical trials is becoming increasingly competitive, with both established players and new entrants vying for market share, which could impact Science 37's ability to attract and retain clients.
  • Data Security Concerns: The sensitive nature of patient data and the potential risks associated with data breaches and privacy concerns present ongoing threats that Science 37 must address to maintain trust and credibility.

Science 37 Holdings Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Science 37 Holdings historical P/E ratio, EBIT, and P/S ratio.

Science 37 Holdings shares outstanding

The number of shares was Science 37 Holdings in 2023 — This indicates how many shares 115.88 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Science 37 Holdings earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Science 37 Holdings's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Science 37 Holdings’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Science 37 Holdings's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Science 37 Holdings Stock splits

In Science 37 Holdings's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Science 37 Holdings.

Science 37 Holdings latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2023-1.43 -0.9  (36.97 %)2023 Q3
6/30/2023-2.55 -1.4  (45.1 %)2023 Q2
3/31/2023-2.75 -2.16  (21.57 %)2023 Q1
12/31/2022-3.6 -2.8  (22.31 %)2022 Q4
9/30/2022-0.18 -0.17  (5.66 %)2022 Q3
6/30/2022-0.2 -0.17  (15.25 %)2022 Q2
3/31/2022-0.23 -0.18  (20.98 %)2022 Q1
12/31/2021-0.21 -0.22  (-2.71 %)2021 Q4
9/30/2021-2.82 -3.06  (-8.5 %)2021 Q3
1

Science 37 Holdings list of shareholders

%
Name
Stocks
Change
Date
0.82949 % Redmile Group, LLC990,41201/28/2024
0.72780 % Pharmaceutical Product Development LLC868,990010/19/2023
0.51298 % Lux Capital Management, LLC612,494010/19/2023
0.23330 % Kent Lake Capital LLC278,560224,33612/31/2023
0.14823 % Glynn Capital Management LLC176,992112/31/2023
0.14212 % Russell Investments Trust Company169,696-28,53112/31/2023
0.13431 % The Vanguard Group, Inc.160,367-1,01812/31/2023
0.13431 % Alphabet, Inc.160,364112/31/2023
0.09824 % MIC Capital Management UK LLP117,295012/31/2023
0.07397 % Alyeska Investment Group, L.P.88,319012/31/2023
1
2
3
4
5
...
10

Science 37 Holdings Executives and Management Board

Mr. David Coman53
Science 37 Holdings Chief Executive Officer, Director
Compensation 8.06 M
Ms. Christine Pellizzari55
Science 37 Holdings Chief Human Resource Officer, Chief Legal Officer
Compensation 4.65 M
Mrs. Darcy Forman48
Science 37 Holdings Chief Delivery Officer
Compensation 3.93 M
Mr. Robert Faulkner60
Science 37 Holdings Independent Chairman of the Board
Compensation 214,998
Ms. Emily Rollins53
Science 37 Holdings Independent Director
Compensation 184,998
1
2
3

Most common questions regarding Science 37 Holdings

What values and corporate philosophy does Science 37 Holdings represent?

Science 37 Holdings Inc represents values centered around innovation, collaboration, and patient-centricity. By using technology-driven solutions, Science 37 aims to advance clinical research and make healthcare more accessible. The company's corporate philosophy focuses on promoting inclusivity, transparency, and scientific integrity in the development of novel therapeutics. Science 37 believes in empowering patients by bringing clinical trials directly to them through remote and virtual trials. By leveraging their proprietary platform, NORA®, Science 37 enables convenient participation and efficient data collection, revolutionizing the way clinical trials are conducted. Overall, Science 37 Holdings Inc strives to improve healthcare outcomes and revolutionize the clinical research landscape.

In which countries and regions is Science 37 Holdings primarily present?

Science 37 Holdings Inc is primarily present in the United States.

What significant milestones has the company Science 37 Holdings achieved?

Some significant milestones achieved by Science 37 Holdings Inc include building a global network of clinical research sites, pioneering the use of decentralized clinical trials, and attracting partnerships with leading pharmaceutical companies. The company has successfully conducted numerous clinical trials across therapeutic areas, contributing to the advancement of medical research. Science 37 Holdings Inc has also received recognition and awards for its innovative approach to clinical trials and its commitment to transforming the traditional research model. With its continuous growth and impact, Science 37 Holdings Inc remains a prominent player in the field of decentralized clinical trials and pharmaceutical research.

What is the history and background of the company Science 37 Holdings?

Science 37 Holdings Inc. is a healthcare technology company specializing in decentralized clinical trials. Founded in 2014, the company offers a unique platform that enables virtual participation in clinical research, thereby increasing patient access and engagement. Science 37 combines advanced telemedicine technology, data analytics, and patient-centric services to streamline the clinical trial process and improve patient outcomes. With a focus on innovative solutions, Science 37 has emerged as a leader in the digital health landscape, empowering patients and researchers to collaborate seamlessly from any location. Through its pioneering approach, Science 37 aims to revolutionize clinical research and transform the future of medicine.

Who are the main competitors of Science 37 Holdings in the market?

The main competitors of Science 37 Holdings Inc in the market include other contract research organizations (CROs) like IQVIA Holdings Inc, PRA Health Sciences Inc, and Medpace Holdings Inc. These companies also provide clinical research services and aim to accelerate the drug development process. However, Science 37 differentiates itself through its unique decentralized clinical trial model, which leverages telemedicine and mobile technology to conduct remote patient visits, enhancing convenience and participation. Despite facing competition in its industry, Science 37's innovative approach positions it as a leading player in revolutionizing clinical trials.

In which industries is Science 37 Holdings primarily active?

Science 37 Holdings Inc is primarily active in the healthcare and clinical research industries.

What is the business model of Science 37 Holdings?

The business model of Science 37 Holdings Inc is centered around providing technology-enabled clinical research services. They aim to transform the traditional clinical trial process by utilizing a decentralized model that allows patients to participate in trials from the comfort of their own homes. Science 37 leverages a cloud-based platform to connect patients, investigators, and clinical research teams, enabling seamless collaboration and data collection. Their innovative approach not only increases accessibility and diversity in clinical trials but also accelerates the development of new medical treatments. With their emphasis on virtual clinical trials, Science 37 Holdings Inc aims to revolutionize the way research is conducted in the healthcare industry.

What is the P/E ratio of Science 37 Holdings 2024?

The Science 37 Holdings P/E ratio is -1.62.

What is the P/S ratio of Science 37 Holdings 2024?

The Science 37 Holdings P/S ratio is 10.4.

What is the AlleAktien quality score of Science 37 Holdings?

The AlleAktien quality score for Science 37 Holdings is 3/10.

What is the revenue of Science 37 Holdings 2024?

The expected Science 37 Holdings revenue is 64.07 M USD.

How high is the profit of Science 37 Holdings 2024?

The expected Science 37 Holdings profit is -411.64 M USD.

What is the business model of Science 37 Holdings

Science 37 Holdings Inc is a company that is revolutionizing global clinical research. The company has developed an innovative business model that combines traditional methods of clinical trials with digital technology to provide a unique and improved clinical research experience. The company offers a range of products and services, including a cloud-based platform called NORA that allows for seamless conduct of clinical trials. The platform also provides a secure environment for collaboration between researchers, physicians, patients, and sponsors. Another product is the mobile clinical research associate (MCRA), which assists research staff in recruiting participants, conducting site checks, and transmitting real-time study protocols to study operators. The company also offers a comprehensive service platform that conducts virtual clinical trials (VCT). This means that clinical research studies can be conducted entirely remotely, without the need for participants or researchers to be physically present. This allows patients to participate in studies that would otherwise be inaccessible due to geographical and time constraints. It also reduces the costs and efforts associated with conducting trials and facilitates data analysis and monitoring. In addition, Science 37 Holdings Inc also has an extensive patient acquisition and retention division that creates an excellent experience for patients and their families. The company utilizes innovative digital communication tools to identify potential participants and engage them throughout the study process. Science 37 Holdings Inc. works closely with leading pharmaceutical and biotech companies to ensure rapid and effective translation of study results from research to practice. By involving patients in the process, the company becomes a key player in the development of evidence-based drugs and therapies. Overall, Science 37 Holdings Inc has taken a unique market position by harnessing the potential of digital technology in clinical research to streamline processes, improve patient retention, alleviate the burden on staff, and accelerate the dissemination of research findings. This company's innovation has the potential to contribute to significant advancements in medicine in the future.

What is the Science 37 Holdings dividend?

Science 37 Holdings pays a dividend of 0 USD distributed over payouts per year.

How often does Science 37 Holdings pay dividends?

The dividend cannot currently be calculated for Science 37 Holdings or the company does not pay out a dividend.

What is the Science 37 Holdings ISIN?

The ISIN of Science 37 Holdings is US8086441081.

What is the Science 37 Holdings ticker?

The ticker of Science 37 Holdings is SNCE.

How much dividend does Science 37 Holdings pay?

Over the past 12 months, Science 37 Holdings paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Science 37 Holdings is expected to pay a dividend of 0 USD.

What is the dividend yield of Science 37 Holdings?

The current dividend yield of Science 37 Holdings is .

When does Science 37 Holdings pay dividends?

Science 37 Holdings pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Science 37 Holdings?

Science 37 Holdings paid dividends every year for the past 0 years.

What is the dividend of Science 37 Holdings?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Science 37 Holdings located?

Science 37 Holdings is assigned to the 'Health' sector.

Wann musste ich die Aktien von Science 37 Holdings kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Science 37 Holdings from 9/14/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/14/2024.

When did Science 37 Holdings pay the last dividend?

The last dividend was paid out on 9/14/2024.

What was the dividend of Science 37 Holdings in the year 2023?

In the year 2023, Science 37 Holdings distributed 0 USD as dividends.

In which currency does Science 37 Holdings pay out the dividend?

The dividends of Science 37 Holdings are distributed in USD.

All fundamentals about Science 37 Holdings

Our stock analysis for Science 37 Holdings Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Science 37 Holdings Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.